Hanne Callewaert | CEO, AstriVax Therapeutics
Hanne has 20+ years life science industry experience exhibiting a unique capability to merge operational execution with strategy development. Equipped with a Master in Biomedical Sciences, a PhD in Medical Sciences and a Master in Intellectual Property law and strong global industry experience in large pharmaceutical industry (GSK Vaccines) as well as into smaller biotech environment (Oxurion, Oncurious, AstriVax Therapeutics). She is passionate developer of vaccines, therapeutic, teams and company culture. Executive experience as public company COO and founding biotech CEO. She also enjoys her busy family life as proud mom of four.
AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022 with a strong focus on immunotherapies. The company develops immunotherapy assets by launching self-amplifying live attenuated viral vectors and target antigens, through the Launch-iT platform. We differentiate in the ability to create qualitative effector T-cells with a unique durable profile. We focus on treating early, clearing infections and hence preventing progression into cancer for e.g. HPV. Our future pipeline could encompass oncology and autoimmune diseases as well.
Powered by: Hyphen Projects | Let's connect: |
Book a ticket
| |||
FAQ Contact Us Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
|
Keep me informed
Download the sponsor brochure
|
© Copyright 2025 by Hyphen Projects